Literature DB >> 10652364

Prolactin-releasing peptide activation of the prolactin promoter is differentially mediated by extracellular signal-regulated protein kinase and c-Jun N-terminal protein kinase.

A Kimura1, M Ohmichi, K Tasaka, Y Kanda, H Ikegami, J Hayakawa, K Hisamoto, K Morishige, S Hinuma, H Kurachi, Y Murata.   

Abstract

Regulation of the mitogen-activated protein kinase (MAPK) family by prolactin-releasing peptide (PrRP) in both GH3 rat pituitary tumor cells and primary cultures of rat anterior pituitary cells was investigated. PrRP rapidly and transiently activated extracellular signal-regulated protein kinase (ERK) in both types of cells. Both pertussis toxin, which inactivates G(i)/G(o) proteins, and exogenous expression of a peptide derived from the carboxyl terminus of the beta-adrenergic receptor kinase I, which specifically blocks signaling mediated by the betagamma subunits of G proteins, completely blocked the PrRP-induced ERK activation, suggesting the involvement of G(i)/G(o) proteins in the PrRP-induced ERK activation. Down-regulation of cellular protein kinase C did not significantly inhibit the PrRP-induced ERK activation, suggesting that a protein kinase C-independent pathway is mainly involved. PrRP-induced ERK activation was not dependent on either extracellular Ca(2+) or intracellular Ca(2+). However, the ERK cascade was not the only route by which PrRP communicated with the nucleus. JNK was also shown to be significantly activated in response to PrRP. JNK activation in response to PrRP was slower than ERK activation. Moreover, to determine whether a MAPK family cascade regulates rat prolactin (rPRL) promoter activity, we transfected the intact rPRL promoter ligated to the firefly luciferase reporter gene into GH3 cells. PrRP activated the rPRL promoter activity in a time-dependent manner. Co-transfection with a catalytically inactive form of a MAPK construct or a dominant negative JNK, partially but significantly inhibited the induction of the rPRL promoter by PrRP. Furthermore, co-transfection with a dominant negative Ets completely abolished the response of the rPRL promoter to PrRP. These results suggest that PrRP differentially activates ERK and JNK, and both cascades are necessary to elicit rPRL promoter activity in an Ets-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652364     DOI: 10.1074/jbc.275.5.3667

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Intra-arterial injection of prolactin-releasing peptide elevates prolactin gene expression and plasma prolactin levels in rainbow trout.

Authors:  T Sakamoto; T Agustsson; S Moriyama; T Itoh; A Takahashi; H Kawauchi; B Th Björnsson; M Ando
Journal:  J Comp Physiol B       Date:  2003-04-10       Impact factor: 2.200

2.  Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor.

Authors:  C J Langmead; P G Szekeres; J K Chambers; S J Ratcliffe; D N Jones; W D Hirst; G W Price; H J Herdon
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

3.  Role of Ras, ERK, and Akt in glucocorticoid-induced differentiation of embryonic rat somatotropes in vitro.

Authors:  Wen Ming Lv; Yan Zhao; Guang Yang; Shi Yun Dong; Guang Hui Zhang; Yu Zhang; Guo Zhong Li; Yu Cheng
Journal:  Mol Cell Biochem       Date:  2014-02-20       Impact factor: 3.396

Review 4.  Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.

Authors:  Safia Ayachi; Frédéric Simonin
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-02       Impact factor: 5.555

Review 5.  Functions of two distinct "prolactin-releasing peptides" evolved from a common ancestral gene.

Authors:  Tetsuya Tachibana; Tatsuya Sakamoto
Journal:  Front Endocrinol (Lausanne)       Date:  2014-11-10       Impact factor: 5.555

Review 6.  Prolactin-Releasing Peptide: Physiological and Pharmacological Properties.

Authors:  Veronika Pražienková; Andrea Popelová; Jaroslav Kuneš; Lenka Maletínská
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.